# agilon health, inc. (AGL) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-04  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/AGL/financials · /stocks/AGL/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/AGL/memo ($2.00, Bearer token).

## Business Model

---
source: coverage-next-full
ticker: AGL
company: agilon health, inc.
step: 01
title: Business Model & Overview
created: 2026-06-04
---

### Step 01 — Business Model & Overview: agilon health, inc. (AGL)

#### 1. Company Summary

agilon health, inc. (NYSE: AGL) is a value-based care (VBC) enablement company that partners with independent primary care physician (PCP) groups to manage Medicare Advantage (MA) beneficiaries under a full-risk, global capitation model. Rather than owning clinics or employing physicians, agilon provides a platform — including payer contracting infrastructure, technology analytics, care management programs, and operational support — that allows existing community physicians to bear and benefit from full MA risk. [S1][S2]

**Elevator pitch:** agilon transforms fee-for-service community primary care physicians into capitated Medicare Advantage partners, keeping patients healthy and capturing the gap between capitation premiums and actual medical costs as "medical margin."

#### 2. Value Chain Layer Map

```
Medicare Advantage Plans (Humana, UHC, BCBS, Aetna, etc.)
    │
    │  Per-member-per-month (PMPM) capitation payments
    ▼
agilon health Platform
    │  • Global capitation contracts with MA plans
    │  • Technology platform (analytics, risk-adjustment coding support)
    │  • Care management programs (high-risk patient identification)
    │  • Operational support (billing, quality, payer relations)
    │  • Shared financial risk structure with physician groups
    ▼
Physician Partner Groups (~30 independent groups, 12 states)
    │  • Primary care physician panels take on full financial risk
    │  • Revenue = capitation PMPM × covered members
    │  • Medical margin = capitation revenue − total medical costs
    ▼
Patients (Medicare Advantage beneficiaries, ~511K covered lives, FY2025)
```

**Revenue flow:** MA plans pay agilon's physician partner entities a fixed PMPM capitation for each enrolled member. agilon recognizes this full capitation as its revenue. Medical costs (hospitalizations, specialist care, pharmacy, etc.) are subtracted to calculate Medical Margin — the economic "gross profit" of the business. agilon receives a platform fee from the physician group's net economics; the physician group retains operating income after agilon's fee. [S2]

#### 3. Business Model Components

##### 3a. Risk-Based Enablement (RBE) Structure

| Component | Description |
|-----------|-------------|
| Entity type | agilon-backed physician group legal entity (RBE) |
| Payer contracts | Global capitation directly from MA plans |
| Physician relationship | Independent physicians contracted with the RBE |
| agilon's role | Platform provider + risk/reward participant |
| Capital deployment | agilon funds initial losses while groups scale to positive medical margin |

The RBE structure allows agilon to consolidate full capitation revenue while keeping physicians autonomous — a critical differentiator vs. employed-physician models (Oak Street Health, ChenMed) and fee-for-service enablement models (Privia Health). [S8]

##### 3b. Revenue Mechanics

- **Revenue = Capitation PMPM × Total MA Members × 12 months**
- PMPM rates are set annually by CMS through the MA bidding process, then negotiated between the MA plan and agilon's RBE
- Revenue risk-adjustment: capitation is adjusted for member acuity (HCC risk scores); risk-adjustment true-ups have been a material negative item in FY2024 and FY2025
- Part D (prescription drug) is included in capitation — a new and material cost driver following the Inflation Reduction Act changes effective 2024

##### 3c. Medical Margin (Economic Gross Profit)

```
Capitation Revenue
  − Total Medical Costs (hospitalizations, specialists, pharmacy, Part D)
= Medical Margin

Medical Margin %  =  Medical Margin / Revenue
```

| FY | Revenue | Medical Margin | MM% |
|----|---------|---------------|-----|
| 2021 | $1,443M | $134M | 9.3% |
| 2022 | $3,307M | $164M | 5.0% |
| 2023 | $4,800M | $299M | 6.2% |
| 2024 | $6,059M | $205M | 3.4% |
| 2025 | $5,922M | ($57M) | (1.0%) |

[S1][S2]

#### 4. Geographic & Partnership Footprint

| Metric | FY2025 | FY2024 |
|--------|--------|--------|
| States | 12 | 13 |
| Geographies | ~28 | ~30 |
| Physician partner groups | ~29 | ~30 |
| MA covered members | ~511K | ~526K |

**Strategy:** agilon exited underperforming markets (notably Hawaii and California in FY2023) and continues rationalizing partnerships. FY2026 guidance assumes members shrink to ~430K as additional underperforming markets/contracts exit. [S2][S6]

#### 5. Revenue Concentration

agilon's top MA plan partners are not individually disclosed, but Humana, UnitedHealth Group, Aetna (CVS), and BCBS affiliates collectively represent the majority of capitation revenue. Single-plan concentration risk is moderated by multi-payer contracting in most markets, but MA plan consolidation is a monitoring item. [S2]

#### 6. Competitive Positioning

| Model Type | Example | Key Difference vs. AGL |
|-----------|---------|------------------------|
| Employed physician VBC | Oak Street Health (CVS), ChenMed | AGL doesn't own clinics; physicians remain independent |
| Non-risk enablement | Privia Health | Privia is fee-for-service focused; AGL takes full capitation risk |
| Risk-bearing IPAs | SCAN, CareMore | Health-plan-owned; AGL is independent platform |
| Self-managed VBC | WellMed (UHC) | Captive physician networks; AGL physicians are community-based |

**Key moat claim:** Physician stickiness — once a physician group takes capitation risk via agilon's platform, switching costs are high (rebuilt payer relationships, analytics dependencies, working capital support). [S8]

#### 7. Source Index

| ID | Source |
|----|--------|
| S1 | SEC EDGAR XBRL — AGL company facts |
| S2 | AGL 10-K FY2024 |
| S6 | AGL_financials/other/business_deep_research.md |
| S8 | AGL_financials/industry/competitive_landscape.md |

## Recent Catalysts

---
source: coverage-next-full
ticker: AGL
company: agilon health, inc.
step: 12
title: Bull vs. Bear Analyst Debate
created: 2026-06-04
---

### Step 12 — Bull vs. Bear: agilon health, inc. (AGL)

> **Note:** Transcripts not loaded. Bull/bear debate constructed from analyst consensus notes, broker research summaries, press release commentary, and news sources (coverage-next-full path).

#### 1. Current Market Context

As of research date (2026-06-04):
- Stock price: ~$82.70 (post 1:25 reverse split; pre-split equivalent ~$3.31)
- Market cap: ~$1.38B
- Enterprise value: ~$1.30B
- Analyst mean price target: ~$58–60 (well below current price)
- Consensus: ~"Hold"
- Street distribution: roughly 3–5 Buy, 8–10 Hold, 2–3 Sell

**The setup is unusual:** AGL stock has rallied >2.5× from its post-guidance-suspension lows on Q1 2026 beat, and the stock now trades ABOVE the analyst mean target. This creates a bifurcated debate between momentum bulls (the turnaround is proving out) and fundamental skeptics (the ROIC story is still unproven; membership is shrinking; litigation overhang). [S5]

#### 2. Bull Case Thesis

##### Argument B1: Q1 2026 MCR Proves the Turnaround is Real

**Claim:** Q1 2026 MCR of ~88% is not a seasonal artifact — it reflects AGL's portfolio rationalization working. The company exited ~85K members (net) in Q1 2026; those were the highest-MCR, most problematic markets. The remaining 426K members represent a quality book that sustainably generates $25–30/member/month medical margin.

**Evidence:** $149M medical margin in Q1 2026 on 426K members; EPS $1.80 vs. $0.93 consensus; FY2026 guidance raised post-Q1.

**Bull price target: $90–95** (Benchmark target cited). Basis: 0.3× EV/Revenue (FY2026E $5.7B revenue) = $1.7B EV → ~$100/share. Or: 10× FY2027E Adj. EBITDA of ~$175M = ~$1.75B EV.

##### Argument B2: FY2026 Is the First Year of a Multi-Year Earnings Recovery

**Claim:** Adj. EBITDA is going from -$230M (FY2025) to +$20M (FY2026E) to potentially +$150–200M (FY2027E). This is a meaningful earnings trajectory that will attract multiple expansion as the company moves from "distressed turnaround" to "recovering growth" framing.

**Evidence:** Q1 2026 adj. EBITDA ~$55M annualizes to $220M — well above FY2026 guidance of $15–25M. Management explicitly guided to positive FY2026 adj. EBITDA for the first time in company history.

##### Argument B3: FY2026 MA Rate Increase (+7.2%) Is the Most Favorable in Years

**Claim:** The combination of AGL's contract resets (which include explicit Part D repricing) and the largest CMS base rate increase in years creates a macro tailwind that the FY2024–2025 cohort did not enjoy.

**Evidence:** CMS finalized FY2026 rate announcement at +7.2% effective base rate change; combined with contract resets, PMPM rates for remaining AGL markets should be materially higher in 2026 than 2025.

#### 3. Bear Case Thesis

##### Argument B1: Q1 Is the Seasonally Best Quarter — Q2–Q4 Will Reveal the True Run-Rate

**Claim:** Q1 is always the best MCR quarter in Medicare Advantage because utilization (hospitalizations, procedures) is seasonally lowest in January–March. The Q1 2026 MCR of ~88% cannot be annualized; Q2–Q4 historically run 3–5 percentage points higher. FY2026 guidance of $15–25M adj. EBITDA (implying full-year medical margin ~$375M) requires Q2–Q4 to hold at MCR ~93–94%. That's far from guaranteed given recent medical cost trend experience.

**Evidence:** AGL's own recent history: Q1 2024 MCR 93.9% vs. full-year FY2024 MCR 96.6%; Q1 2023 MCR ~91% vs. full-year 93.8%. The seasonal pattern is real and meaningful.

**Bear price target: $21** (JPMorgan cited). Basis: Discounted to ~0.3× book value + option value on turnaround.

##### Argument B2: Membership Contraction Limits Revenue Recovery Even If MCR Normalizes

**Claim:** AGL is guiding to ~430K members at FY2026 year-end — 18% below the FY2025 peak. Revenue will be ~$5.7B in FY2026 and ~$5.5–5.8B in FY2027 even in a recovery scenario. This is a business whose top line is shrinking, not growing. At the current stock price (~$82 post-split), the market is pricing in a revenue recovery that requires new partnership additions the company has not yet committed to.

**Evidence:** FY2026 guidance implies flat-to-declining members; FY2027 new partner additions would require 2–3 year ramp periods to add meaningful revenue; revenue decline from peak unlikely to reverse until FY2028+.

##### Argument B3: Securities Litigation + Balance Sheet Fragility Create Asymmetric Downside Risk

**Claim:** The securities class action (class period Feb 2024–Aug 2025; filed Dec 2025) could result in a $50–200M settlement that materially impacts the cash balance ($182M FY2025). At the guided ~$125M FY2026 year-end cash, a $100M settlement payment would leave AGL below minimum operating liquidity, potentially requiring a dilutive equity raise at an inopportune time.

**Evidence:** AGL acknowledged the lawsuit in its FY2025 10-K. Class period aligns with a $250M+ guidance miss. Similarly-sized MA misstatement cases have settled at $40–150M range.

#### 4. Analyst Debate Summary

| Dimension | Bull | Bear |
|-----------|------|------|
| Q1 2026 MCR ~88% | Structural improvement; portfolio exit working | Seasonal; Q2–Q4 will revert to ~93–96% |
| Membership decline to 430K | Right-sizing; remaining book high quality | Revenue ceiling effect; growth requires 2–3yr ramp |
| FY2026 guidance $15–25M EBITDA | Floor, not ceiling; Q1 beat implies upside | Seasonality means Q2–Q4 could disappoint |
| Legal/cash risk | Will settle for modest amount; cash sufficient | Could force dilutive raise; litigation tail is long |
| New CEO O'Rourke | VBC veteran; Q1 beat is his first data point | Only 1 month in office as of Q1 report; unproven |

#### 5. Bull Case — 3 Bullets

- **Q1 2026 MCR of ~88% demonstrates portfolio rationalization is working:** Exiting ~85K underperforming members dramatically improved the remaining book's economics, and FY2026 contract resets explicitly price in Part D and risk-adjustment realities for the first time — creating a structurally cleaner earnings base.
- **First guided positive EBITDA year (FY2026 $15–25M) marks an inflection that should command multiple expansion:** As AGL transitions from "cash-burning turnaround" to "EBITDA-positive platform company," it should re-rate from deep distress multiples toward healthcare services comps (5–10× EBITDA), which implies meaningful upside from current levels if guidance holds.
- **+7.2% CMS MA base rate in FY2026 provides the largest external PMPM tailwind in company history:** Combined with AGL's contract resets, this creates an asymmetric setup where even modest MCR normalization produces outsized medical margin — the bull case is that Q2–Q4 2026 remain more favorable than historical seasonality suggests, driven by the MA rate increase absorbing the residual V28 headwind.

#### 6. Bear Case — 3 Bullets

- **Q1 is the seasonally best Medicare Advantage quarter; the ~88% MCR is not the sustainable run-rate:** Q2–Q4 historically run 3–5 percentage points above Q1 on MCR; if FY2026 full-year MCR averages 95%+ (as in FY2024), the $375M guided medical margin collapses to near-zero, and the securities class action + balance sheet fragility could force a dilutive equity raise.
- **Membership is planned to shrink to 430K in FY2026 (vs. 526K peak) and recovery requires 2–3 year physician group ramp:** Revenue will be structurally below $6B through at least FY2028, and the current ~$1.38B market cap implies >15× EV/FY2026 EBITDA — a premium multiple for a still-recovering, litigation-laden company with a largely unproven new CEO.
- **Securities class action creates $50–200M tail liability at precisely the moment when cash is thin (~$125M guided FY2026 year-end):** Any settlement or adverse legal development in FY2026–2027 could exhaust liquidity and trigger a dilutive capital raise, re-testing the stock near its prior crisis lows.

#### 7. Source Index

| ID | Source |
|----|--------|
| S2 | AGL 10-K FY2024 |
| S5 | Analyst consensus and broker targets |
| S6 | AGL_financials/other/business_deep_research.md |

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/AGL/memo

## Navigation

- Overview: /stocks/AGL
- Financials: /stocks/AGL/financials
- Thesis (this page): /stocks/AGL/thesis
- Investment Memo: /stocks/AGL/memo
- Coverage universe: /stocks